The p53 tumour suppressor protein functions as a guardian against genotoxic stress. This function is mediated in part by the transcriptional activation of genes involved in cell-cycle arrest, apoptosis, DNA repair and autophagy. The activity of p53 is regulated by a complex array of post-translational modifi cations, which function as a code to determine cellular responses to a given stress. In this chapter we highlight recent advances in our understanding of this code, with particular reference to lysine methylation, and discuss implications for future research.
Introduction
Transcription factor p53 is perhaps regarded as one of the most important guardians of the genome, and exerts its tumour suppressive function in response to a number of genotoxic stresses by regulating cellular processes such as apoptosis, DNA repair, senescence and autophagy [1, 2] . p53 exerts its function in 'reading' the code and translating it into a functional cellular response [12] . In the past few years a number of methyltransferase and demethylase enzymes have been discovered to target p53, and this chapter aims to give a summary of these recent advances, with particular focus on lysine methylation. How these events effect p53 tumour suppressor function, and the questions they raise for future research into cell-cycle regulation, will also be discussed.
Methylation of p53 Monomethylation
The p53 protein contains a large number of lysine and arginine residues, providing the potential for regulation by methylation events. Indeed, to date, p53 has been demonstrated to be a target for no fewer than fi ve KMT enzymes (summarized in Table 1 ). Methylation of p53 was fi rst described by Chuikov et al. [13] , who demonstrated that the mono-methyltransferase Set7/9 [Su(var)3-9, Enhancer-of-zeste, Trithorax] could mediate methylation of Lys 372 in the C-terminal regulatory domain of p53 ( Figure 1 ). Structural analysis of the Set7/9-p53 complex indicated that the recognition of p53 by Set7/9 paralleled the interaction of the enzyme with its previously described H3 histone substrate [ 14] , in that the active site of the enzyme interacts with a short recognition motif in the substrate. Methylation of p53 by Set7/9 is under DNA-damage regulation, and Lys 372 -methylated p53 is recruited very rapidly to target promoters Figure 1 . Overview of p53 methylation and other modifications Schematic representation of p53 highlighting the major protein domains and the main sites of PTM under normal cellular conditions and during stress. The C-terminus of p53 has been enlarged to highlight the arginine and lysine residues targeted for methylation. The enzymes responsible for creating the modifications are indicated (orange text denotes kinases responsible for phosphorylation, green text denotes acetyltransferase enzymes, purple text denotes ubiquitin ligases, blue text denotes methyltransferases responsible for creating monomethyl marks, and red text denotes methyltransferases responsible for introducing dimethyl marks). The effector proteins which recognize methyl marks in p53 are also highlighted. TAD, transactivation domain; PRD, proline-rich domain; DBD, DNA-binding domain; OD, oligomerization domain; RD, C-terminal regulatory domain. Lysine and arginine are denoted by their one-letter amino acid codes.
after exposure of cells to stress. Lys 372 methylation induced the stabilization of p53 protein levels and the expression of p53-responsive genes such as p21 and MDM2 [13] . The importance of Lys 372 methylation for activating p53 function was highlighted by the use of a Set7/9 mutant lacking enzyme activity: the expression of p53-responsive genes and stabilization of p53 protein levels failed to increase even after treatment of cells with drugs which induce DNA damage [13] . Moreover, in the absence of Lys 372 methylation, DNA-damageinduced acetylation of p53 was also impaired [15] . This suggests that methylation at Lys 372 is able to stimulate subsequent acetylation, thus providing one explanation for the enhanced stability and activity of p53 seen after methylation by Set7/9. Indeed, methylation of p53 was seen to precede acetylation during the DNA-damage response [15] and in a Set7/9-knockout mouse model, cells from mutant mice failed to methylate or acetylate p53 in response to DNA damage and showed defects in cell-cycle arrest and apoptosis [16] . Similar to what is seen in cells with compromised p53 function, cells from Set7/9 mutant mice were also predisposed to oncogenic transformation [16] . Rather surprisingly, however, the mice used in the above study appear grossly normal and fail to develop tumours, in contrast with p53-knockout mice [16] . Therefore while the loss of Set7/9 may predispose to cancer, it does not appear suffi cient to cause cancer. This suggests that the abrogation of p53 tumour suppressor activity is not absolute in Set7/9 mutant mice. Indeed, two recent independent reports examining the phenotype of Set7/9-defi cient mice have also questioned the impact of methylation in the p53-mediated DDR (DNA-damage response) [17, 18] . Both studies demonstrate that the cell-cycle arrest, apoptotic and tumour suppressor functions of p53 are unaffected in mutant mice [17, 18] . Athough the precise explanation for this observed discrepancy between mouse models remains elusive, it is possible that functionally redundant mechanisms exist that can bypass the requirement for Set7/9-mediated methylation in the regulation of p53 activity. p53 can also be targeted by the mono-methyltransferases Smyd2 [19] and Set8 [20] . Unlike Set7/9, which activates the transcriptional and pro-apoptotic functions of p53, Smyd2 and Set8 act to suppress the p53-dependent DNAdamage response (Figure 1 ). Set8 mediates the methylation of Lys 382 , and this modifi cation directly competes with the formation of acetylated Lys 382 , a modifi cation linked to the DDR [8] . As one might expect, the endogenous levels of Set8 mRNA and protein are themselves down-regulated during the DDR [20] . Set8-mediated methylation of p53 therefore acts in antagonism to p53 protein stabilization and limits the expression of genes such as p21 and PUMA (p53 up-regulated modulator of apoptosis). This transcriptional effect is also mediated in part by the decreased association of Lys 382 -methylated p53 with the promoters of its target genes [20] . Interestingly, this effect appears to be promoter-specifi c, since 'weak' p53 targets, such as Bax and NoxA, appear unaffected by Set8 protein levels, and the expression of some genes involved in DNA repair are actually suppressed by Set8 siRNA (small interfering RNA) [20] . The authors of this study suggest that Lys 382 methylation might therefore present a mechanism that provides a measured response to mild insults, allowing for p53-dependent repair of DNA without induction of cell death. Smyd2 targets its monomethylation activity to Lys 370 of p53, and similar to what was observed for Set8, the levels of Lys 370 methylation decrease after DNA damage [19] . While Smyd2-mediated methylation of p53 does not directly have an impact on its stability or localization, it once again affects the ability of p53 to associate with DNA, and cells lacking Smyd2 are consequently more susceptible to DNAdamage-induced apoptosis [19] . It therefore seems apparent that there is some redundancy in the methylation-dependent mechanisms that cells can utilise to suppress the inappropriate activation of p53-mediated events. Dimethylation p53 can also be modifi ed by enzymes that mediate the addition of higher-order methylation states. G9a and Glp/EHMT1 are closely related histone methyltransferases that mediate the di-and tri-methylation of lysine residues on the tail of histone H3. They are also known to methylate p53, although they appear to favour the generation of dimethylated p53 both in vitro and in cells [21] . G9a and Glp do not interact directly with p53, but are recruited via their association with the acidic domain of MDM2 [22] . MDM2, in addition to encouraging the degradation of p53, is known to inhibit p53 transcriptional activity by the recruitment of corepressor proteins to p53. Suv39H1 is also recruited to p53 via an interaction with MDM2, although this enzyme does not appear to target p53 directly [22] . Since G9a and Glp are known to methylate Lys 9 in histone H3, a hallmark of silenced chromatin, it would not be surprising if methylation of p53 by these enzymes played a similar role to repress p53 transcriptional activity. Indeed, G9a and Glp are present at p53-responsive promoters and act in concert with MDM2 to repress the transcription of p53 reporter genes. This is believed to be mediated both by the methylation of histones and of p53 itself [22] . Methylation of p53 by G9a and Glp occurs at Lys 373 and the levels of methylation are not affected under conditions of DNA damage, despite an increase in the total amount of cellular p53. This suggests that methylation only occurs on the inactive form of p53 (Figure 1 ). In agreement with this hypothesis, loss of G9a or Glp results in a dramatic increase in the number of apoptotic cells seen in response to DNA damage [21] . In addition, cells demonstrate an increased sensitivity to p53-dependent cell-cycle arrest and p53-induced cellular senescence [22] . As one might expect, the p53-activator protein ARF (alternative reading frame) relieves methylation-induced repression of p53 by inhibiting binding of Glp to MDM2, and thus its recruitment to p53 [22] . It is interesting to note that G9a is up-regulated in several cancer types compared with normal tissues, and Glp is overexpressed in brain tumours, multiple myelomas, and head and neck cancers [21] . This indicates that abnormal levels of these enzymes could be responsible for promoting tumour cell growth in certain cancers. MS (mass spectrometry) analysis of endogenous p53 has also identifi ed other sites of dimethylation in addition to Lys 373 . Both the Lys 370 mark and the Lys 382 mark can exist in the dimethyl state [23] , although the enzymes which mediate the addition of the second methyl group have, to date, not been described. Both marks act as a recognition motif for the tandem Tudor domain of 53BP1 (p53-binding protein 1), a known coactivator of p53-dependent transcription [23, 24] . In this sense, it is interesting to note that while both the Lys 370 and Lys 382 monomethylation marks act to repress p53 transcriptional activity, the dimethyl states on both lysine residues are associated with p53 transcriptional activation.
Recruitment of effector proteins to p53 methyl marks
The functional consequence of any given PTM is mediated, at least in part, by the recruitment of effector proteins which contain structural domains that recognize modifi cations such as lysine methylation. To date, a number of domains are known to associate with methylated lysine residues, and these form the 'Royal family' of so-called reader domains. The sequence and structural requirements involved in the recognition of histone modifi cations by these reader proteins, and their effect on transcriptional processes have been well described previously [12] . What is important to note is that these reader domains are also capable of recognizing modifi cation marks in other non-histone proteins. Indeed, interactions between methylated lysine residues in p53 with chromodomains, Tudor domains and MBT (malignant brain tumour) domains have all been described [16, [23] [24] [25] and are detailed briefl y below.
Methylation of p53 by Set7/9 under conditions of DNA damage is associated with a corresponding and subsequent increase in p53 acetylation [15, 16] . TIP60 [Tat (transactivator of transcription)-interactive protein 60 kDa], a member of the MYST [MOZ (monocytic leukaemic zinc-fi nger protein), Ybf2/Sas3, Sas2 and TIP60] family of acetyltransferases, is one of the enzymes responsible for this observed acetylation, and regulates the cell-cycle arrest and apoptotic functions of p53 [26, 27] . TIP60 contains a chromodomain and was shown to interact with p53 in cells overexpressing active Set7/9 enzyme, or in cells undergoing a DDR [16] . This interaction could be competed by the addition of a methylated p53 peptide, and in vitro binding assays indicated a preferential interaction of TIP60 with methylated p53. This, in addition to the observation that TIP60 does not associate with p53 in Set7/9-knockout MEFs (mouse embryonic fi broblasts) [16] , suggests that the interaction is specifi c for p53 methylation at Lys 372 . Since TIP60 shares close homology with other MYST family members, it is possible that the Lys 372 mark could recruit other acetyltransferase enzymes to methylated p53. For example, hMOF [human orthologue of fl y Mof (male absent on fi rst)] would be a good candidate since it has also been demonstrated to target p53 for acetylation [26] .
As mentioned previously, the tandem Tudor domain of 53BP1 is known to bind to two separate dimethyl marks in p53 [23, 24] . Dimethylation of Lys 370 was observed in cells treated with adriamycin, and this methyl mark strongly recruited 53BP1. This recruitment did not occur with a p53 mutant lacking the Lys 370 methylation site, or in cells expressing a 53BP1 mutant containing amino acid substitutions within its tandem Tudor domain [24] . This, therefore, strongly suggests that the interaction is methyl-dependent and occurs via Lys 370 . 53BP1 appears to function as a p53 coactivator protein, since its recruitment to dimethyl-Lys 370 promotes the expression of downstream genes such as p21, MDM2 and PUMA [24] .
Dimethylation at Lys 382 also represents a high-affi nity ligand for 53BP1 both in vitro and in cells, and once again, an intact tandem Tudor domain is required for 53BP1 recognition of methylated p53 [23] . The recruitment of 53BP1 to dimethylated Lys 382 shows parallels with its recruitment to dimethylLys 370 , in that it is DNA-damage responsive. However, in the context of dimethylated Lys 382 , 53BP1 does not appear to affect the transactivation activity of p53 [23] . Instead, it appears to be involved in stabilizing p53 levels in cells under DNA-damage conditions. This stabilization results, not from an increase in p53 expression, but via a decrease in the proteasomal-dependent degradation of p53 [23] . The signifi cance of 53BP1 recognition of multiple methyl marks is currently unknown, as is the molecular understanding of how the same effector protein can have different physiological outcomes, depending on its recruitment site. It is probable that the dimethylation marks on p53 do not exist in isolation, and that the repertoire of modifi cations present under any specifi c condition acts to fi ne-tune the functional outcome of effector protein recruitment.
Interestingly, the Lys 382 methylation mark in p53 can also be recognized by the MBT-repeat-containing protein L3MBTL1 [25] . Unlike 53BP1, L3MBTL1 is preferentially recruited to monomethylated Lys 382 , binding in a manner reminiscent of the interaction between L3MBTL1 and methylated histone H4K20 (histone H4 methylated on Lys 20 ) [28] . The monomethyl mark at Lys 382 is mediated by the enzyme Set8, and overexpression of this methyltransferase in cells promotes the interaction between p53 and L3MBTL1. This interaction is methylation-dependent, since an enzyme-dead mutant of Set8 does not have the same affect, and L3MBTL1 cannot interact with a p53 mutant lacking the Set8 monomethylation site [25] . Most importantly, L3MBTL1 is recruited by Lys 382 -methylated p53 to the promoters of its target genes, where it acts to repress transcription and consequently effects cell proliferation [25] . This is consistent with previous observations that have linked L3MBTL1 with transcriptional repression [29] , and others which indicate that L3MBTL1 can mediate chromatin compaction around the promoters of E2F-target genes in a fashion dependent on the recognition of histone methyl marks [30] . Since Set8-mediated methylation of p53 occurs under basal conditions [20] , it is likely that L3MBTL1 is stabilized at the chromatin of p53-target genes in undamaged cells, where it acts to suppress the transcription of genes involved in cell-cycle arrest and apoptosis. Under DNA damage the levels of Set8, and consequently Lys 382 monomethylation, decline [20] , resulting in a reduced association of L3MBTL1 with p53 target genes [25] . This would be expected to alleviate the transcriptional repression of DNA-damage-responsive genes such as p21 and PUMA.
The removal of methyl marks in p53
For many years lysine methylation was believed to be a permanent modifi cation due to its stability. However, it was subsequently demonstrated that, similar to other forms of PTM, lysine methylation events are dynamic in nature, and can be removed by enzymes known as KDMs (lysine demethylases). To date, a demethylase enzyme has been described for most histone methylation marks, yet studies on non-histone proteins are less complete. p53 was found to interact with LSD1 in cells [24] , a demethylase enzyme known to target mono-and di-methyl lysine marks on histones. LSD1 specifi cally mediates the demethylation of mono-and di-methyl Lys 370 in vitro, yet in cells appears to show a preference for the dimethyl mark, since LSD1 siRNA did not have an impact on monomethyl-Lys 370 levels [24] . LSD1 was found to act as a repressor of p53-dependent transcription, and this function was dependent on the demethylase activity of the enzyme. Reducing LSD1 levels in cells also sensitized them to apoptosis induced by the addition of DNA-damaging agents [24] . These results are consistent with the observation that dimethylation of p53 at Lys 370 is a mark of active transcription. It is highly probable that LSD1 mediates its repressive function by regulating the interaction between p53 and 53BP1, which is partly dependent on the presence of the Lys 370 dimethyl mark [24] .
Cross-talk between p53 PTMs
In histones, a large number of residues can be modifi ed by PTMs, and these modifi cations usually co-exist in discrete patterns. This results from cross-talk between these events, as certain modifi cations can infl uence the occurrence of other subsequent modifi cations [31] . The same regulatory processes have also been observed on non-histone proteins, and p53 provides a perfect example. As discussed previously, methylation by Set7/9 activates p53-dependent transcription [13, 15, 16] . Another consequence of this modifi cation is the inhibition of methylation at a nearby lysine residue by Smyd2 [19] . Since Smyd2-mediated methylation negatively regulates p53 activity, it makes sense that these two methylation events are co-regulated. The methylation of Lys 372 by Set7/9 appears to block the recruitment of Smyd2 to p53, thus preventing Lys 370 methylation [19] (Figure 2) . It is interesting to note, however, that this cross-talk appears to be unidirectional, as Smyd2-mediated methylation does not impinge on methylation by Set7/9. This may be important in permitting a rapid activation of p53 in response to stress [19] . Methylation by Set7/9 has also been indicated to promote the subsequent acetylation of p53 at C-terminal lysine residues such as Lys 373 and Lys 382 [15] . Although this observation can be explained in part by the recruitment of TIP60 via its chromodomain to methylated p53 [16] , how Figure 2 . Examples of cross-talk between p53 modifications (A) Lysine methylation inhibits subsequent methylation at a neighbouring site. Under DNA damage, Set7/9 methylates p53 at Lys 372 , which disrupts the interaction between Smyd2 and p53. This prevents methylation of the repressive Lys 370 mark by Smyd2. (B) Lysine methylation promotes further p53 PTM. The monomethyl Lys 372 mark promotes subsequent p53 acetylation by a number of enzymes. How p53 methylation regulates the activity of enzymes such as p300 and PCAF is currently unknown, but TIP60 is directly recruited to the Lys 372 methyl mark via its chromodomain. (C) Lysine methylation is mutually exclusive for other modifications that occur at the same site. Methylation of the repressive Lys 373 and Lys 382 marks in p53 will prevent their modification by acetylation. Lysine is denoted by the one-letter amino acid code.
methylation regulates the activity of other non-chromodomain acetyltransferases, such as p300 (E1A-associated protein of 300 kDa) and PCAF {p300/ CBP [CREB (cAMP-response-element-binding protein)-binding protein]-associated factor}, is not fully understood (Figure 2 ). Set7/9-mediated methylation of p53 may promote its subsequent acetylation, but other methylation events appear to be mutually exclusive with acetylation. This refl ects the fact that the methylation and acetylation events compete for the same lysine residue (Figure 2 ). For example, monomethylation of Lys 382 by Set8 is associated with reduced levels of acetylation at Lys 382 . Under DNA-damage conditions, when Set8 methylation is reduced, increased Lys 382 acetylation levels are observed [20] . Methylation of p53 at Lys 373 by G9a and Glp would also be expected to interfere with subsequent acetylation at Lys 373 , although this has yet to be demonstrated experimentally. However, since acetylation of p53 results in stimulation of p53 activity, and methylation by G9a and Glp is associated with p53 inhibition, it seems likely that this interplay will occur. In many ways this regulation would mirror the mutual exclusivity observed between methylation and acetylation of histone H3K9 (histone H3 methylated at Lys 9 ), where acetylation is associated with active transcription and methylation with repressed transcription [31] .
Given the close proximity of methylation events mediated by Set7/9 and G9a/Glp, cross-talk might also be expected to occur here, in a similar fashion to what was observed for methylation by Set7/9 and Smyd2 [19] . Methylation in the Lys 370 -Lys 373 region of p53 could also infl uence phosphorylation of p53 at Ser 371 , which is mediated by protein kinase Cα [32] . An analogous example has already been described for the retinoblastoma protein, where methylation of a lysine residue within a CDK (cyclin-dependent kinase)-consensus motif inhibits subsequent phosphorylation of neighbouring serine residues [33] . A second example is seen on histones, where methylation-phosphorylation interplay has been described for H3K9 and H3S10 (histone H3 phosphorylated on Ser 10 ) [31] . Since p53 can be heavily modifi ed by a number of PTMs, it is likely that many more examples of cross-talk have yet to be unearthed.
Concluding remarks and perspectives
It is becoming increasingly apparent that proteins such as p53 can be extensively modifi ed in a manner analogous to that observed for histones. The plethora of modifi cations that can occur on histone tails, of which lysine methylation provides a substantial contribution, act in concert with one another to determine the temporal and spatial expression of specifi c sets of genes during development, differentiation and the DDR [31] . Similarly, one could assume that the numerous possible combinations of modifi cation on p53 would fi ne-tune its transcriptional response under a variety of stress conditions. Although many PTMs on p53 have been extensively examined in isolation, it will be of utmost importance to investigate how they coexist and interplay with one another. Only then will we be able to fully understand how the broad range of p53 activities are regulated in a cell-specifi c, condition-specifi c and promoter-specifi c fashion. Although the majority of studies highlighted in this chapter have focused on the impact of lysine methylation on p53-dependent apoptosis and cell-cycle arrest, one should not forget that p53 activity contributes to many other cellular processes, such as DNA repair, senescence and autophagy [1, 2] . The impact of lysine methylation on these additional p53-related functions has yet to be extensively investigated. Further insight into the mechanism by which these methylation events mediate their functional consequences is also required, as many of the enzymes and proteins involved in 'writing', 'reading' and 'erasing' these marks represent novel therapeutic targets.
Regulation of p53 activity by methylation is not restricted solely to lysine residues. The p53 coactivator Strap is known to recruit PRMT5 to p53 during the DDR, when it is responsible for the methylation of p53 at arginine residues in the oligomerization domain [34] . This has an impact on the nuclear accumulation of p53 and its ability to associate with the promoters of genes involved in cell-cycle arrest. Modifi cation of arginine residues is therefore important in determining promoter specifi city and may regulate the switch between cell-cycle arrest and apoptosis. However, such cell-fate decisions probably result from a combination of signals. For example, lysine methylation within the C-terminus of p53 may function to regulate the overall transcriptional activity of the protein [13, 15, 16, 19, 20] , whereas arginine methylation within the oligomerization domain functions to target this activity towards specifi c p53-responsive genes [34] .
Finally, it is important to remember that many of the enzymes responsible for creating, reading and erasing methylation marks in p53 also target a number of other proteins involved in tumour suppression. For example, Set7/9 and Smyd2 both target the retinoblastoma protein [33, 35, 36] , whereas Set7/9 and LSD1 have been shown to create and remove methyl marks on E2F-1 [37] . In both cases, methylation infl uences the occurrence of other PTMs or the recruitment of effector proteins. Modifi cation 'codes' are therefore a common occurrence on a number of tumour suppressor proteins. The potential of any given 'writer', 'reader' or 'eraser' of these codes as a target for cancer therapy can therefore only be determined from studies that broadly defi ne their effect on proteins in addition to p53. 
Summary

